Ligand Pharmaceuticals (LGND) Income from Continuing Operations (2010 - 2026)

Ligand Pharmaceuticals has disclosed Income from Continuing Operations across 17 years of filings, most recently posting 13345000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 13345000.0, up 68.56% year-over-year; the trailing twelve-month figure through Mar 2026 was 153559000.0 (up 215.79% YoY), and the FY2025 annual result was 124453000.0, up 3186.63% from the prior year.
• Income from Continuing Operations came in at 13345000.0 for Q1 2026 at Ligand Pharmaceuticals, down from 44784000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 117273000.0 in Q3 2025 to a low of 51911000.0 in Q2 2024.
• The 5-year median for Income from Continuing Operations is 2290000.0 (2023), against an average of 9157411.76.
• Across the five-year window, Income from Continuing Operations slumped 2366.86% in 2024 and jumped 1735.15% in 2025, its largest moves.
• Ligand Pharmaceuticals' Income from Continuing Operations stood at 14534000.0 in 2022, then jumped by 225.14% to 18188000.0 in 2023, then plunged by 270.93% to 31088000.0 in 2024, then soared by 244.06% to 44784000.0 in 2025, then tumbled by 129.8% to 13345000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 13345000.0 (Q1 2026), 44784000.0 (Q4 2025), and 117273000.0 (Q3 2025), per Business Quant data.